Core Viewpoint - The company has entered into a joint venture agreement with NAGAWA Pharmaceutical Co., Ltd and Mirxes Pte Ltd to establish a new company in Hong Kong, focusing on anti-aging products and solutions [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of HKD 50 million, with the company holding 75% ownership, NAGAWA Pharmaceutical 20%, and Mirxes Pte Ltd 5% [1] - The new company aims to invest in and operate research and sales of anti-aging products in Hong Kong and selected Asia-Pacific countries [1] Group 2: Strategic Objectives - This collaboration addresses the changing consumer demands for "healthy lifespan" and "beauty lifespan," enhancing customer lifetime value and loyalty [1] - The initiative marks a shift from providing external beauty services to offering comprehensive beauty and health solutions [1] - The venture is expected to create significant cross-selling opportunities, improve the company's brand image, establish a competitive advantage in the medical anti-aging sector, and ultimately generate sustainable revenue streams for long-term shareholder value [1]